Ultrahuman today announced findings from one of the largest real-world, free-living sleep and metabolism studies ever conducted.
The study, uploaded on medRxiv and undergoing peer review, was developed in partnership with a multinational academic research group including Stanford University's Snyder Lab, Bangor University's Hans-Peter Kubis, and La Trobe University's Driller Lab.
The analysis covers 227,860 nights of concurrent, anonymized data from 5,859 adults across 100 countries, drawn from the Ultrahuman platform and M1 continuous glucose monitor (CGM) – one of the longest-running consumer CGM programmes in existence.
Unlike studies relying on a single sensor, this research was only possible because of Ultrahuman's integrated health ecosystem. It combines sleep architecture data captured through the Ultrahuman platform with Ultrahuman's clinically validated Metabolic Score from the M1 CGM.
This simultaneous capture in free-living conditions makes the dataset's scale and precision unprecedented, and builds on previous Ultrahuman metabolic health studies published in Scientific Reports. And Ultrahuman is working on further studies with Mayo Clinic, Harvard, Pfizer, Unilever and more.
The headline findings:
Consistency beats duration for metabolic health: Sleep timing regularity emerged as a strong predictor of metabolic health.
Small margins, major consequences: A difference of just 10-15% in day-to-day sleep timing variability separated users with elite, athlete-level glucose control from those nearing pre-diabetes. This turns sleep regularity into a powerful lever: even small, sustained improvements in sleep consistency can meaningfully regulate glucose metabolism over time.
Reframing What We Know About Sleep
For decades, public health messaging has centred on a single metric: get seven to eight hours. This research challenges that framing and suggests the importance of consistency has been overlooked.
Sleep duration matters – but the data suggests that when you sleep, and how reliably you stick to that schedule, may be an equally powerful determinant of metabolic health.
When the research team applied machine learning to identify what most separated the metabolically healthy from those approaching dysfunction, sleep timing consistency emerged as the single strongest discriminator.
On nights with poor sleep quality, participants' overnight glucose averaged 6.4 mg/dL higher, and time spent within a healthy glucose range fell by 13.9%. Cardiovascular strain followed the same pattern: sleep heart rate ran 9 bpm higher, HRV dropped by 7ms, and the minimum nocturnal heart rate was elevated by 6 bpm. It's a constellation of signals associated with a body under stress.
Critically, the people displaying the most severe patterns were not ill. They had no diagnosis and had self-reported as healthy. But their overnight physiology was already tracking toward pre-diabetic territory, and the data points to a single cause – irregularity of when they went to bed.
The Silent Cost of Poor Glucose Control
Chronically elevated blood sugar — even in the sub-diabetic range — is associated with impaired cognitive function, disrupted appetite regulation, and increased long-term risk of type 2 diabetes and cardiovascular disease, two of the leading causes of preventable death globally.
What this dataset suggests is that sleep timing irregularity may be quietly nudging otherwise healthy people toward that trajectory — years before any clinical diagnosis.
This research also points toward the broader potential of integrated health ecosystems. By understanding the relationship between sleep patterns and metabolic markers at the population scale, it becomes possible to generate meaningful metabolic insights even for people who do not wear a CGM.
This is the underlying promise of an integrated health ecosystem: the ability to infer what cannot always be directly measured, and to do so with the rigour of data collected when both sensors are present.
Regulators are arriving at similar conclusions, and the FDA is explicitly targeting connected health devices as tools for managing chronic disease – including pre-diabetes.
"We've long suspected that circadian consistency was upstream of metabolic health — but the scale of this dataset allows us to see it with unusual clarity for the first time," said Ultrahuman CEO Mohit Kumar. "What's striking is how accessible the intervention is. The data shows that going to bed at roughly the same time each night is one of the most powerful metabolic levers most people aren't using."
About Ultrahuman
Ultrahuman is a global health technology company building one of the world's most comprehensive health ecosystems. With innovations such as the Ultrahuman M1 CGM, Blood Vision, Ultrahuman Home, and Cycle & Ovulation Pro, Ultrahuman empowers people to act early, live better, and unlock their peak potential. In 2025, Ultrahuman was named one of TIME's World's Top HealthTech Companies, recognised for advancing accessibility and preventive healthcare.
